PARG and cancer: ARH3 deficiency is therefore a potential novel PARP1 inhibitor resistance mechanism, similar to what has been described for loss of PARG, which causes PARP inhibitor resistance in cancer cells due to stabilization of the PARylation signal (Gogola et al., 2018).